Spero Therapeutics

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Spero Therapeutics reports progress in drug candidates and financial stability

Spero Therapeutics showcased progress in key drug candidates and financial stability.
Efficient management of expenses and strong cash position support future operations.
Challenges include successful Phase III trials and proof of concept for key treatments.
Opportunities lie in market potential for drug candidates and positive financial outlook.

Spero Therapeutics advances clinical programs and strengthens financial position

Spero Therapeutics demonstrated strong clinical and financial performance in Q1 2023, with a robust pipeline and efficient cost management.
While facing timeline challenges and the need for regulatory milestones, the company's strengths in infectious disease treatments and strategic partnerships present growth opportunities.
By addressing challenges, leveraging strengths, and capitalizing on opportunities, Spero is poised for continued success and potential market leadership in the pharmaceutical sector.

Spero Therapeutics reports Q2 progress with strategic leadership changes

Spero Therapeutics reported Q2 revenues of $2.7 million with a net loss of $11.9 million, holding $77.7 million in cash.
Progress in late-stage clinical programs and management changes signal strategic advancements and leadership continuity.
Challenges include managing R&D investments, competitive market dynamics, and clear execution of growth strategies.
Opportunities lie in revenue growth from milestones, pipeline expansion, differentiation strategies, and strategic partnerships.

Spero Therapeutics reports strong Q3 performance amidst strategic shifts

Spero Therapeutics showcased solid revenue generation and cash reserves in Q3 2023, underpinned by strategic partnerships and pipeline advancements.
While facing challenges such as increased expenses and impairment costs, the company's leadership changes and innovative programs position it for long-term success.
Opportunities lie in upcoming clinical data releases, expansion of product pipelines, and substantial revenue potential from key partnerships, signaling a promising outlook for Spero.

Spero Therapeutics excels in antibiotic development with strong financial backing

Spero Therapeutics demonstrated strong performance in advancing key programs and securing financial support, positioning the company for future growth.
While facing challenges in enrollment and funding, the opportunities in addressing critical infections present a promising outlook for Spero Therapeutics.

Spero Therapeutics reports Q2 revenue growth amidst leadership transition

Spero Therapeutics showcased solid revenue but faced rising R&D costs and leadership changes.
The company's financial stability is supported by cash reserves and expected milestone payments.
Opportunities lie in pipeline advancements, upcoming data releases, and strategic investor communication.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Applied Blockchain Inc

AST SpaceMobile

Federated Hermes

Raymond James

FHI, RJF, ASTS, APLD and SPRO have been added to the Zacks Rank #1 (Strong Buy) List on November 15, 2024.

New Strong Buy Stocks for November 15th

Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to earnings of $0.02 per share a year ago.

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates

Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the third quarter ended September 30, 2024, and provided a business update.

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

In vitro data on SPR719 show low propensity for resistance development in NTM-PD MAC strains when administered as a single agent and in combination with standard of care agents

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024

Phase 1 study showed significant lung uptake and enhanced epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of SPR719 (active moiety of SPR720) Phase 1 study showed significant lung uptake and enhanced epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of SPR719 (active moiety of SPR720)

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 AM ET Company Participants Shai Biran - Senior Director Investor Relations Sath Shukla - Chief Executive Officer Esther Rajavelu - CFO and Chief Business Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Gavin Clark-Gartner - Evercore ISI Ritu Baral - TD Cowen Operator Good afternoon and welcome to the Spero Therapeutics Second Quarter 2024 Financial Results Conference Call. At this time all participants are in listen-only mode.

Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript

Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.23 per share a year ago.

Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the second quarter ended June 30, 2024, and provided a business update.

Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update

CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Monday August 5th, 2024 at 4:30 p.m. ET to report financial results for second quarter 2024 and provide an update on its business and pipeline.

Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024

Amplify Energy Corp.

Oramed Pharmaceuticals

When discussing micro-cap stocks, it's important to recognize their general overlap with the world of penny stocks. These stocks trade as shares of companies with market capitalizations between $50 million and $300 million.

3 Micro-Cap Moonshots for Fearless Investors

CAMBRIDGE, Mass., July 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on May 28, 2024, the Compensation Committee of Spero's Board of Directors approved the grant of an aggregate of 227,500 restricted stock unit awards (RSUs) to new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The RSUs are being granted as an inducement material to each of the new employees becoming an employee of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the H.C. Wainwright 2 nd Annual BioConnect Investor Conference at NASDAQ, to take place on Monday, May 20, 2024, at the NASDAQ World Headquarters New York, NY. Details are as follows:

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial and operational results for the quarter ended March 31, 2024.

Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2024 financial results and provide an update on its business and pipeline on Wednesday, May 15, after the market close. The Company does not intend to host a conference call, and anticipates resuming quarterly earnings calls at the time it announces second quarter 2024 results.

Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024

CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on April 29, 2024, the Compensation Committee of Spero's Board of Directors approved the grant of an aggregate of 10,833 restricted stock unit awards (RSUs) to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, or the 2019 Inducement Plan. The RSUs are being granted as inducements material to the new employee, becoming an employee of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Spero Therapeutics, Inc. has continued to build and advance its pipeline over the past several months and is now on the verge of generating landmark data with multi-bagger potential. Spero has excellent downside protection and additional upside from the payments from the Tebipenem HBr deal with GSK. Spero's significant undervaluation and potential path forward are highlighted in the peer comparison.

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Spero Therapeutics, Inc. (SPRO) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of a loss of $0.18 per share. This compares to earnings of $0.55 per share a year ago.

Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates

Spero Therapeutics, Inc. (SPRO) Q4 2023 Earnings Call Transcript

CAMBRIDGE, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Wednesday, March 13, 2024 at 4:30 p.m. ET to report its fourth quarter and full year financial results and provide an update on its business and pipeline.

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it has received clearance by the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) application, to evaluate SPR206 in a Phase 2 clinical study. SPR206 is a novel, intravenously (IV) administered next-generation polymyxin antibiotic for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by MDR Gram-negative bacterial infections.

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel therapies for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Cowen 44th Annual Healthcare Conference, which is taking place March 4-6, 2024, at the Boston Marriott Copley Place in Boston, MA. Details are as follows:

Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference

In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients

Spero Therapeutics Provides Corporate Update and 2024 Outlook

$95 million in development milestones payable over two years, as part of GSK license agreement $95 million in development milestones payable over two years, as part of GSK license agreement

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Ted Jenkins - Vice President, Investor Relations and Strategic Finance Sath Shukla - Chief Executive Officer Kamal Hamed - Chief Medical Officer Steve Dipalma - Interim Chief Financial Officer and Treasurer Conference Call Participants Louise Chen - Cantor Fitzgerald Boobalan Pachaiyappan - H.C. Wainwright Good afternoon and welcome to the Spero Therapeutics Third Quarter 2023 Financial Results Conference Call.

News for Spero Therapeutics Stock (SPRO)